10-Q: Werewolf Therapeutics Faces Going Concern Doubt Amid Cash Burn

Werewolf Therapeutics, an early-stage biopharmaceutical company, reported substantial doubt about its ability to continue as a going concern, with significant cash burn and increased net losses.

Summary

• Werewolf Therapeutics reported a net loss of $52.441 million for the nine months ended September 30, 2025, an increase from $50.115 million for the same period in 2024.
• Cash and cash equivalents decreased significantly to $65.711 million as of September 30, 2025, from $110.995 million at December 31, 2024.
• The company used $49.268 million in cash for operating activities during the nine months ended September 30, 2025, compared to $41.936 million in the prior year period, indicating increased cash burn.
• Collaboration revenue was $0 for the nine months ended September 30, 2025, down from $1.885 million in the prior year, as the last material performance obligation under the Jazz Pharmaceuticals agreement was completed in June 2024.
• Research and development expenses decreased to $37.897 million for the nine months ended September 30, 2025, from $40.707 million in the prior year, primarily due to lower manufacturing costs for WTX-330 and JZP898, partially offset by increased clinical trial costs for WTX-124 and WTX-330.
• General and administrative expenses decreased to $13.362 million for the nine months ended September 30, 2025, from $14.424 million in the prior year.
• Proceeds from the At-The-Market (ATM) offering of common stock significantly decreased to $3.6 million for the nine months ended September 30, 2025, from $21.1 million in the prior year, reflecting lower transaction volume and average share price.
• The company's third tranche commitment of $10.0 million under the K2HV Loan Agreement expired on June 30, 2025, without being drawn upon.
• An amendment to the employment agreement for Chief Technology Officer Chulani Karunatilake was made on September 9, 2025, modifying non-change in control severance benefits.

Sentiment

Score: 2

Explanation: The sentiment is overwhelmingly negative due to the explicit 'going concern' warning, significant cash burn, increasing net losses, and the failure to draw on available debt tranches. While there are ongoing clinical trials and preclinical progress, the fundamental financial viability is under severe question, overshadowing any operational positives.

Positives

• Research and development expenses decreased by $2.810 million for the nine months ended September 30, 2025, compared to the same period in 2024.
• General and administrative expenses decreased by $1.062 million for the nine months ended September 30, 2025, compared to the same period in 2024.
• The company reported initial data from the WTX-124 combination dose escalation cohorts and initiated monotherapy dose expansion arms in June 2024, with all expansion arms actively enrolling or fully enrolled.
• Phase 1 of the WTX-330 clinical trial was completed in Q1 2025, and a Phase 1b/2 clinical trial was initiated in Q1 2025, with active patient enrollment.
• Preclinical data for WTX-712 and WTX-518 were presented at the AACR Annual Meeting in April 2024, demonstrating unique mechanisms and robust immune activation.
• The company nominated its first INDUCER development candidate, WTX-1011, targeting STEAP1, with preclinical data showing silenced peripheral activity and prevented cytokine release.

Negatives

• Substantial doubt exists about the company's ability to continue as a going concern for at least twelve months from the filing date.
• Net loss increased to $52.441 million for the nine months ended September 30, 2025, from $50.115 million in the prior year period.
• Cash and cash equivalents significantly decreased to $65.711 million as of September 30, 2025, from $110.995 million at December 31, 2024.
• Net cash used in operating activities increased to $49.268 million for the nine months ended September 30, 2025, from $41.936 million in the prior year period.
• No collaboration revenue was recognized for the nine months ended September 30, 2025, compared to $1.885 million in the prior year period.
• Proceeds from the ATM offering decreased significantly to $3.6 million for the nine months ended September 30, 2025, from $21.1 million in the prior year period.
• The third tranche commitment of $10.0 million under the K2HV Loan Agreement expired on June 30, 2025, without being drawn, limiting potential funding.

Risks

• Substantial doubt about the ability to continue as a going concern for at least twelve months, requiring additional liquidity.
• Limited operating history, significant operating losses since inception, and no products approved for commercial sale, with no expectation of product sales revenue for the foreseeable future.
• Need for substantial additional funding to finance operations and complete development and commercialization of product candidates; failure to raise capital could lead to delays or termination of programs.
• Early stage of development for product candidates, requiring successful completion of extensive preclinical and clinical development before regulatory approval can be sought.
• High dependence on the success of initial INDUKINE and INDUCER molecules, which are in early development stages and require significant additional development.
• The PREDATOR platform approach is unproven, and there is no certainty of developing products of commercial value.
• Manufacturing INDUKINE and INDUCER molecules is subject to risk due to their novel class as multi-domain biologics with protease cleavable linkers, and they have never been produced on a commercial scale.
• Preclinical studies and clinical trials are expensive, time-consuming, difficult to design and implement, and involve uncertain outcomes, with results of earlier studies not necessarily predictive of future results.
• Potential for substantial delays in the commencement or completion, or termination or suspension, of clinical trials, leading to increased costs and delayed revenue generation.
• Difficulties in patient enrollment in clinical trials could delay or adversely affect clinical development activities.
• Development of WTX-124, WTX-330, and future product candidates in combination with third-party drugs means limited or no control over the safety, supply, regulatory status, or approval of such drugs.
• Substantial competition from major pharmaceutical, specialty pharmaceutical, and biotechnology companies.
• Reliance on third parties to conduct preclinical studies and clinical trials, with risks if they do not successfully carry out contractual duties or meet deadlines.
• Reliance on third parties to produce preclinical, clinical, and commercial supplies of all current and future product candidates due to lack of own clinical manufacturing capabilities.
• Reliance on the license agreement with Harpoon Therapeutics, Inc. for patent rights, with risks of losing these rights if obligations are not met.
• Proprietary position depends partly on manufacturing, formulation, or method-of-use patents, which may not prevent competitors from using the same product candidate for another use.
• Past material weaknesses in internal control over financial reporting, and risk of future inability to implement and maintain effective internal control.
• Cyberattacks or deficiencies in cybersecurity could result in information theft, data corruption, operational disruption, damage to reputation, or financial loss.
• Business disruptions and unfavorable economic conditions could seriously harm business, future revenue, and financial condition, and increase costs and expenses.
• Risks associated with marketing product candidates internationally, if approved, including differing regulatory requirements, economic instability, and compliance with foreign laws.
• Strategic transactions could impact liquidity, increase expenses, and present significant distractions to management.
• Failure to comply with Nasdaq continued listing requirements could lead to delisting and negatively impact stock price and access to capital markets.
• Stock price volatility related or unrelated to operations.
• Principal stockholders and management own a significant percentage of common stock, potentially exerting significant control over stockholder approval matters.
• Broad discretion regarding the use of cash and cash equivalents, which may not enhance operating results or stock price.
• No intention to pay dividends on common stock, limiting returns to stock appreciation.
• Increased costs and management time devoted to compliance initiatives and corporate governance practices as a public company.
• Potential for costly and damaging liability claims from testing product candidates in the clinic or following commercial sale.
• Inability to obtain orphan drug designation or exclusivity, or loss of such exclusivity.
• Ongoing regulation and potential restrictions or withdrawal from the market for approved products, with substantial penalties for non-compliance.
• Risk of criminal sanctions, civil penalties, and reputational harm for non-compliance with FDA regulations restricting promotion for unapproved uses.
• Uncertainty in obtaining Breakthrough Therapy, Fast Track, Priority Review, or PRIME designations, and such designations not guaranteeing faster development or approval.
• Accelerated approval, if granted, may not lead to faster development or approval and does not increase the likelihood of marketing approval.
• Disruptions at the FDA and other government agencies from funding cuts, personnel losses, regulatory reform, and government shutdowns could hinder timely approval.
• Current and future legislation may increase the difficulty and cost to obtain reimbursement for products.
• Subject to U.S. and foreign export control, import, sanctions, anti-corruption, and anti-money laundering laws, with non-compliance leading to criminal/civil liability.
• Changes in and uncertainty surrounding U.S. and international trade policies could have a material adverse impact on business.

Future Outlook

The company expects to incur substantial operating losses and negative cash flows for the foreseeable future and will require substantial additional funding to support continuing operations and growth strategy. Future funding is expected to come from public or private equity offerings, debt financings, or collaboration agreements. The ability to draw on the fourth tranche of the K2HV Loan Agreement (up to $20.0 million) is available through May 1, 2026, subject to lender review and consent. The company is eligible for up to an additional $515.0 million in development and regulatory milestones and $740.0 million in sales-based milestones from the Jazz collaboration, though achievement is uncertain. The timing and amount of operating expenditures will depend on the scope, progress, and costs of research and development, manufacturing, regulatory approvals, commercialization efforts, and intellectual property protection.

Management Comments

• We believe there is substantial doubt about our ability to continue as a going concern for at least twelve months from the date these condensed consolidated financial statements are issued in this Form 10-Q.
• We are currently evaluating plans to mitigate the conditions which raise substantial doubt about our ability to continue as a going concern.
• We will be required to raise additional funds through an additional public equity financing, establish collaborations with or license our technology to other companies, or seek alternative means of financial support in order to continue to fund our operations in the future.
• There can be no assurance, however, that additional fundraising will be successful and available on terms acceptable to us, or at all.
• If we are unable to raise capital when needed or on acceptable terms, we may be forced to delay, reduce, or eliminate certain costs related to our operations and research and development programs.

Industry Context

Werewolf Therapeutics operates in the highly competitive biopharmaceutical industry, specifically focusing on oncology and immune-mediated conditions with its novel PREDATOR platform. The industry faces significant regulatory hurdles, including complex and lengthy approval processes, and is subject to evolving government policies on drug pricing and reimbursement, as evidenced by the Inflation Reduction Act and recent executive orders from the Trump administration. The company's reliance on third-party manufacturers and CROs is common in the sector but introduces supply chain and quality control risks. Geopolitical tensions and cybersecurity threats also pose broader industry challenges, potentially impacting global supply chains and data integrity. The company's early-stage development of INDUKINE and INDUCER molecules places it among numerous competitors developing similar immunotherapies, highlighting the high risk and capital-intensive nature of drug development.

Comparison to Industry Standards

• The company's WTX-124 product candidate, an IL-2 based cancer therapy, faces competition from numerous clinical and preclinical IL-2 molecules from companies such as Anaveon AG, Ascendis Pharma A/S, Asher Biotherapeutics, Inc., Aulos Bioscience, Inc., BioNTech SE, Cue Biopharma, Inc., DEKA Biosciences, Inc., DragonFly Therapeutics, Inc., Merck & Co., Inc., Medicenna Therapeutics Corp., F. Hoffmann-La Roche AG, Synthekine, Inc., Teva Pharmaceutical Industries Ltd., and Xilio Therapeutics, Inc., in addition to the approved Proleukin (aldesleukin).
• WTX-330, an IL-12 therapy, competes in a field with no currently approved IL-12 therapies for cancer but faces competition from other IL-12 cytokine programs in clinical and preclinical development from companies including DEKA Biosciences, Inc., DragonFly Therapeutics, Inc., IMUNON, Juno Therapeutics, Inc. (Bristol-Myers Squibb Company), OncoSec Medical Incorporated, PDS Biotechnology, Philogen S.p.A., Sonnet BioTherapeutics, Inc., Strand Therapeutics Inc., Turnstone Biologics Corp. (partnered with Takeda Pharmaceutical Company Limited), Xilio Therapeutics, Inc., and Zymeworks Inc.

Management Changes

Legal Proceedings

• The company is exposed to potential product liability risks inherent in the research, development, manufacturing, marketing, and use of biopharmaceutical products.
• The company may be involved in lawsuits to protect or enforce its patents or the patents of its licensors, which could be expensive, time-consuming, and unsuccessful.
• The company may be subject to claims challenging the inventorship or ownership of its patents and other intellectual property.
• The company may be subject to claims that it or its employees have wrongfully used or disclosed confidential information of competitors or are in breach of non-competition or non-solicitation agreements.
• The company could be adversely affected by several significant administrative law cases decided by the U.S. Supreme Court in 2024 (Loper Bright Enterprises v. Raimondo, Corner Post, Inc. v. Board of Governors of the Federal Reserve System, Securities and Exchange Commission v. Jarkesy), which could introduce additional uncertainty into the regulatory process and result in legal challenges to actions by federal regulatory agencies.
• The implementation of the Inflation Reduction Act (IRA) is currently subject to ongoing litigation challenging the constitutionality of its Medicare drug price negotiation program.
• The FDA's decision on orphan drug exclusivity, following the Catalyst Pharms, Inc. v. Becerra case and a subsequent federal district court decision, is currently under appeal and its implications are unclear.
• The company is subject to U.S. and certain foreign export control, import, sanctions, anti-corruption, and anti-money laundering laws, with non-compliance potentially leading to criminal/civil liability and enforcement actions.

Related Party Transactions

• In May 2022, the company entered into a sublease agreement with Crossbow Therapeutics, Inc., for which entities affiliated with MPM Capital are also beneficial owners. Luke Evnin, Ph.D., chair of the company's board, co-founded MPM Capital, and Briggs Morrison, a board member, serves as Executive Partner of MPM Capital and CEO of Crossbow. The sublease ended in March 2024, and a $0.2 million security deposit was remitted to Crossbow.

Stakeholder Impact

• **Shareholders:** Face substantial dilution risk from future equity offerings, potential loss of investment if the company cannot continue as a going concern, and stock price volatility. The concentration of ownership by principal stockholders and management could limit influence.
• **Employees:** Risk of job reductions or delays in research and development programs if additional funding is not secured. The company's ability to attract and retain qualified personnel is critical for future success.
• **Customers (future):** Potential delays or termination of product development could mean that needed therapies are not brought to market.
• **Creditors (K2HV):** The K2HV Loan Agreement is secured by substantially all of the company's assets (excluding intellectual property), and contains restrictive covenants and events of default that could lead to acceleration of obligations.
• **Suppliers/CROs/CMOs:** Potential for delays in payments or termination of contracts if the company faces financial difficulties, impacting their business.

Next Steps

• Release interim data from the WTX-124 monotherapy and combination expansion arms during the fourth quarter of 2025.
• Provide feedback from the End of Phase 1 meeting with regulatory authorities for WTX-124 during the fourth quarter of 2025.
• Provide an update on the WTX-330 clinical trial and guidance on potential further development plans during the fourth quarter of 2025.
• Continue preclinical development of WTX-712, WTX-518, WTX-921, and WTX-1011.
• Evaluate plans to mitigate conditions raising substantial doubt about the ability to continue as a going concern.
• Seek additional funding through public equity financing, collaborations, licensing, or alternative financial support.

Key Dates

Recommendation

The explicit 'substantial doubt about our ability to continue as a going concern' is a critical red flag for investors. This, combined with increasing net losses, a significant reduction in cash and cash equivalents, and a sharp decline in capital raised through the ATM offering, indicates severe financial distress. While the company has ongoing clinical trials, the fundamental financial viability is in question, making the stock a high-risk investment with a strong likelihood of further value erosion. The failure to draw on an available debt tranche further underscores liquidity challenges. Investors should consider exiting their positions.

Keywords

Biopharmaceutical, Oncology, Immunotherapy, Cancer, PREDATOR platform, INDUKINE, INDUCER, WTX-124, WTX-330, Clinical trials, Drug development, SEC filing, 10-Q, Going concern, Cash burn, Biologics, Regulatory approval, Pharmaceuticals, Biotechnology